Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 4/20 | 0.41 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.41 |
| ▸ | TRIM33 | Q9UPN9 | 2/20 | 0.41 |
| ▸ | TYR | P14679 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.35 |
| ▸ | THRA | P10827 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.34 |
| ▸ | KMO | O15229 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14102883 | 0.84 | TDP1 (0.39) | ERN1TRIM24TRIM33TYRTDP1 | |
| SCHEMBL25333361 | 0.82 | AR (0.48) | ERN1TRIM24TRIM33TYRLPAR1 | |
| SCHEMBL25333318 | 0.81 | ERN1 (0.47) | ERN1TRIM24TRIM33TYRTDP1 | |
| SCHEMBL25334978 | 0.79 | ALDH1A1 (0.47) | ERN1TRIM24TRIM33TYRCA1 | |
| SCHEMBL14662307 | 0.79 | SOS1 (0.44) | ERN1CA1CA2TDP1SOS1 | |
| SCHEMBL14662079 | 0.79 | KMO (0.42) | ERN1CA1CA2TDP1SOS1 | |
| SCHEMBL29428769 | 0.79 | AR (0.41) | ERN1TRIM24TRIM33TYRTDP1 | |
| SCHEMBL21855911 | 0.77 | TDP1 (0.43) | ERN1TRIM24TRIM33TYRTDP1 | |
| SCHEMBL25332470 | 0.77 | ALDH1A1 (0.46) | TDP1MAPT | |
| SCHEMBL30509805 | 0.76 | ERN1 (0.42) | ERN1TRIM24TRIM33TYRHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116234550-B | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)股份有限公司 | 2024-12-27 | — | — | CN | disclosed |
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | ZHEJIANG GENFLEET THERAPEUTICS CO., LTD. (CN) | 2024-10-31 | — | — | US | disclosed |
| EP-4223753-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-08-09 | — | — | EP | disclosed |
| EP-4223753-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Genfleet Therapeutics (Shanghai) Inc. (CN) | 2023-08-09 | — | — | EP | disclosed |
| CN-116234550-A | Aromatic formyl substituted tricyclic compound and preparation method and application thereof | 劲方医药科技(上海)有限公司 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022063101-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 劲方医药科技(上海)有限公司 | 2022-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240360154-A1 | AROYL SUBSTITUTED TRICYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | BTK, WEE1, WEE2 | ERN1 3554/4885TRIM24 2807/4885TRIM33 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.